Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized comparison of abciximab i.v. versus i.c. in primary PCI patients with STEMI and effects on infarct size and microvascular obstruction

Next Previous
X
Search
Trial Profile

Randomized comparison of abciximab i.v. versus i.c. in primary PCI patients with STEMI and effects on infarct size and microvascular obstruction

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abciximab (Primary) ; Abciximab (Primary)
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms LIPSIABciximab-STEMI

    • Most Recent Events

    • 17 Nov 2011 Results reporting the endpoint of aborted myocardial infarction published in the International Journal of Cardiology.
    • 01 May 2011 Results published in Clinical Research in Cardiology.
    • 28 Aug 2010 Results from mid-term follow-up at 6 months presented in an abstract at the Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top